101 MET ECD shedding and poor DFS Table 2: Baseline characteristics for the entire sample population (n = 156). Clinico-histopathological characteristic No. of patients # % Sex Male 96 62 Female 60 38 Age at diagnosis Mean (range) 63.5 (34.0–87.0) Smoking No 57 37 Yes 97 62 Missing 2 1 Alcohol No 119 76 Yes 37 24 Subsite Alveolus and gingiva 20 13 Lip 5 3 Tongue 56 36 Floor of mouth 47 30 Buccal mucosa 28 18 Cancer stagea,b I 14 9 II 30 19 III 33 21 IV 77 49 Missing 2 1 Treatment Surgery 49 31 Surgery and radiotherapy 107 69 aBased on pTNM, which was assessed according to the 7th edition of the AJCC. bAll included patients are assessed as pM = 0 by clinical and/or histological examination. Evaluation of N-terminal MET immunoreactivity across cancers using a scatter plot based analysis and its association with prognosis N-terminal MET immunoreactivity is generally low across cancers and it shows no relationship with disease-free survival or overall survival of the corresponding patients (Supplementary Figs. 5A, B). This was confirmed for overall survival by performing a receiver operating characteristic curve analyses for average A2H2-3 immunoreac4
RkJQdWJsaXNoZXIy MTk4NDMw